You just read:

Isarna Therapeutics and Santaris Pharma Announce License Agreement for the Development of Next Generation Oligonucleotides to Treat TGF-Beta-Mediated Diseases

News provided by

Santaris Pharma A/S

Jan 08, 2014, 08:00 ET